Clinical Trials Logo

Joint Prosthesis clinical trials

View clinical trials related to Joint Prosthesis.

Filter by:
  • None
  • Page 1

NCT ID: NCT03123289 Terminated - Joint Prosthesis Clinical Trials

Novel Gallium 68 Citrate in Orthopedic Infections

Start date: March 6, 2017
Phase: Phase 2
Study type: Interventional

In the proposed study, our aim is to evaluate the uptake of 68Gallium-citrate in patients with failed joint prosthesis and compare it with that of conventional 18fluorine-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) scan. We will perform PET/CT scan with 68Gallium citrate and 18F-FDG in subjects with failed hip or knee prosthesis. Both 68Gallium-citrate and 18F-FDG scans, done within 24-48 hours from each other, will be performed within 4 weeks before surgical evaluation/revision of the hardware.

NCT ID: NCT02177097 Completed - Joint Prosthesis Clinical Trials

Chronic Pain, Inflammation and Infection After Joint Replacement

Start date: January 2010
Phase: N/A
Study type: Observational

Revision surgery after total hip or knee arthroplasty is an ongoing issue due to an increasing number of primary surgeries. Patients seek physicians due to pain. The cause is divided between loosening, infection or chronic pain. Some are operated on the suspicion of a chronic infection. However, postoperative microbiological testing does not always correlate with the suspicion and the operation may have been superfluous. The objective is to employ a highly advanced diagnostic algorithm based on state of the art diagnostic techniques in order to improve the basis of preoperative diagnosis. Through this approach treatment can be given according to the causal problem.

NCT ID: NCT00211926 Completed - Clinical trials for Staphylococcal Infections

StaphVAX Immunogenicity in Orthopedic Implant Patients

Start date: December 2004
Phase: Phase 3
Study type: Interventional

S. aureus is the most common pathogen involved in prosthetic joint infection. StaphVAX® is a vaccine to prevent these infections, which conjugates the purified capsular polysaccharides of S. aureus to a carrier protein. It is currently being evaluated for future licensing. This study aims to demonstrate the safety and immunogenicity of a single dose of StaphVAX in patients who are candidates for knee or hip arthroplasty.